S'abonner

Dissemination of ST131 and ST393 community-onset, ciprofloxacin-resistant Escherichia coli clones causing urinary tract infections in Korea - 07/08/11

Doi : 10.1016/j.jinf.2009.11.004 
Mi Young Lee a, 1, Hyeon Jin Choi b, 1, Ji Young Choi b, Minsuk Song c, Yoosuk Song c, Shin-Woo Kim d, Hyun-Ha Chang d, Sook-In Jung e, Yeon-Sook Kim f, Hyun Kyun Ki g, Jun Seong Son h, Ki Tae Kwon i, Sang Taek Heo j, Joon-Sup Yeom k, Sang Yop Shin l, Doo Ryeon Chung m, Kyong Ran Peck m, Jae-Hoon Song a, m, , Kwan Soo Ko a, b,
a Asian-Pacific Research Foundation for Infectious Diseases (ARFID), Seoul, South Korea 
b Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, 300 Chunchun-dong, Jangan-ku, Suwon 440-746, South Korea 
c Trinity-Pawling School, Pawling, NY, USA 
d Kyungpook National University Hospital, Daegu, South Korea 
e Chonnam National University Medical School, Gwangju, South Korea 
f Chungnam National University Hospital, Daejeon, South Korea 
g Konkuk University Hospital, Seoul, South Korea 
h East-West Neo Medical Center, Kyunghee University, Seoul, South Korea 
i Daegu Fatima Hospital, Daegu, South Korea 
j Gyeongsang National University School of Medicine and Gyeongsang Institute of Health Sciences, Jinju, South Korea 
k Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea 
l Jeju National University Hospital, Jeju National University School of Medicine, Jeju, South Korea 
m Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, South Korea 

Corresponding author. Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, 300 Chunchun-dong, Jangan-ku, Suwon 440-746, South Korea. Tel.: +82 31 299 6223; fax: +82 31 299 6229.Corresponding author. Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, South Korea. Tel.: +82 2 3410 0320; fax: +82 2 3410 0328.

Summary

Objective

Ciprofloxacin-resistant Escherichia coli is growing concern in clinical settings. In this study, we investigated the distribution of virulence determinants and phylogenetic groups among community-onset, ciprofloxacin-resistant E. coli isolates causing urinary tract infections (UTIs) in Korea. In addition, the evidence of clonal spread in the community was also examined.

Methods

From November 2006 to August 2007, 543 community-onset E. coli isolates causing UTIs were collected as part of a multicenter surveillance study. In vitro susceptibility testing was performed using broth microdilution method. Distribution of virulence determinants and phylogenetic groupings were examined. In addition, multilocus sequence typing (MLST) analysis was performed.

Results

In vitro antimicrobial susceptibility testing revealed that 154 isolates (28.4%) were ciprofloxacin-resistant. Of these, 129 ciprofloxacin-resistant E. coli isolates were further characterized. As a result of phylogenetic subgrouping, we found that phylogenetic subgroup D was the most predominant (46 isolates, 35.7%), followed by B2 (44 isolates, 34.1%), A (21 isolates, 16.3%), and B1 (18 isolates, 14.0%). MLST analysis showed 48 sequence types (STs). The most prevalent ST was ST131 (32 isolates, 24.8%), followed by ST393 (23 isolates, 17.8%). While all ST131 isolates belonged to phylogenetic subgroup B2, which is known to be a highly virulent, all ST393 isolates belonged to subgroup D. ST131 and ST393 showed different profiles of virulence factors; papA, papG allele III, and traT genes were significantly more prevalent in ST131 than in ST393 (p values, <0.001).

Conclusions

Based on genotyping, it is suggested that epidemic and virulent ciprofloxacin-resistant E. coli clones such as ST131 and ST393 have disseminated in Korea. However, the diversity of CTX-M genes in ST131 isolates may indicate that ESBL genes have been acquired independently or several ESBL-producing, ciprofloxacin-resistant E. coli clones may have disseminated in the Korean community.

Le texte complet de cet article est disponible en PDF.

Keywords : Surveillance, ST131, ST393, Multilocus sequence typing (MLST)


Plan


© 2009  The British Infection Society. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 60 - N° 2

P. 146-153 - février 2010 Retour au numéro
Article précédent Article précédent
  • Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong
  • Pak-Leung Ho, Pui-Ying Lo, Kin-Hung Chow, Eric H.Y. Lau, Eileen L. Lai, Vincent C.C. Cheng, Richard Y. Kao
| Article suivant Article suivant
  • The virulence variability of different Acinetobacter baumannii strains in experimental pneumonia
  • Matthieu Eveillard, Christophe Soltner, Marie Kempf, Jean-Paul Saint-André, Carole Lemarié, Catherine Randrianarivelo, Harald Seifert, Michel Wolff, Marie-Laure Joly-Guillou

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.